论文部分内容阅读
依诺沙星(Enoxacin)投产后已广泛用于临床,获得良好疗效。现对该药在上市后治疗51例感染的临床疗效和不良反应简要小结如下。共治疗泌尿系感染34例和呼吸系感染17例。病例均系华山医院感染门诊患者。男17例,女34例,平均年龄51.8±13.5岁。依诺沙星片为武汉制药厂市售商品,每片0.2g。剂量为0.4～0.6g/d,分二次服用。疗程视病种而定,呼吸系感染一般为7～14次,泌尿系感染为5～7天。疗效判断按照卫生部颁发的抗菌药物临床研究指导标准分为痊愈、显效、进步和无效4级,痊愈和显效者作有效计。 治疗结果:依诺沙星对51例细菌感染的有效率为82.3％(见表一)。
Enoxacin has been widely used in clinic after it is put into production, and has obtained good curative effect. The drug is now listed in the treatment of 51 cases of clinical efficacy and adverse reactions summary is as follows. A total of 34 cases of urinary tract infection and respiratory infection in 17 cases. Huashan Hospital cases were outpatients infected patients. There were 17 males and 34 females, with an average age of 51.8 ± 13.5 years. Enoxacin tablets for the Wuhan Pharmaceutical Factory commercial products, each piece 0.2g. The dose of 0.4 ~ 0.6g / d, divided into two doses. Depending on the disease course of treatment, respiratory infections are generally 7 to 14 times, urinary tract infections for 5 to 7 days. Efficacy in accordance with the judgments issued by the Ministry of Health clinical research guidelines for antimicrobial agents are divided into healed, markedly effective, progressive and ineffective level 4, effective recovery and effective persons. Treatment outcome: Enoxacin was effective in 51 cases of bacterial infections in 82.3% (Table 1).